New Concepts in the Management of Medullary Thyroid Cancer - Management of Medullary Thyroid Cancer

This live webinar series is an educational program that addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with medullary thyroid cancer (MTC).

Archived NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease
T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.
Optimizing Patient Outcomes - New Primary Therapy Options for Stage III-IV Hodgkin Lymphoma

With the addition of two new regimens for the treatment of stage III-IV advanced Hodgkin lymphoma, it is important for the interprofessional oncology care team to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, un

Optimizing Patient Outcomes - Understanding the Mismatch Repair Deficient (dMMR)/Microsatellite-High (MSI-H) Treatment Options in Upper Gastrointestinal Cancers

The standards of care for the treatment of MSI-H/dMMR esophageal, esophagogastric junction, and gastric cancers are constantly evolving.

NCCN 2025 Nursing Program: Advancing Oncology Nursing™

This program will cover essential updates in clinical oncology practice, including emerging treatment modalities and patient management strategies.

NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer
In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.
Optimizing Patient Outcomes - Targeted Therapies for Thyroid Carcinoma

Thyroid carcinoma is a rare disease; however, it is the seventh most common cancer diagnosed in those assigned female at birth. Greater attention to rare diseases is needed to improve treatment options in general, and specifically for anaplastic thyroid carcinoma.

Optimizing Patient Outcomes - Metastatic Castration-Resistant Prostate Cancer: Systemic Therapy Updates
It is important to stay up to date with the latest therapy options available, review the latest mCRPC systemic therapy recommendations, and understand the data behind them.
NCCN Tumor Boards: Treatment Options and Navigating Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.
NCCN 2025 Breast Cancer Congress with Updates from the 2024 San Antonio Breast Cancer Symposium
This program offers expert insights into current recommendations of care for patients with breast cancer and includes the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.

Pages

Subscribe to RSS - Live Webinar